Granzyme B-expressing B cells have been shown to be an important regulatory B cell subset in humans. However, it is unclear which subpopulations of B cells express GZMB under normal conditions and which protocols effectively induce ex vivo expansion of GZMB + B cells. We found that in the peripheral blood of normal individuals, plasmablasts were the major B cell subpopulation that expressed GZMB. However, when using an in vitro plasmablast differentiation protocol, we obtained only 2% GZMB + B cells. Nevertheless, using an expansion mixture containing IL-21, anti-BCR, CpG oligodeoxynucleotide, CD40L, and IL-2, we were able to obtain more than 90% GZMB + B cells after 3 d culture. GZMB + B cells obtained through this protocol suppressed the proliferation of autologous and allogenic CD4 + CD25 2 effector T cells. The suppressive effect of GZMB + B cells was partially GZMB dependent and totally contact dependent but was not associated with an increase in effector T cell apoptosis or uptake of GZMB by effector T cells. Interestingly, we showed that GZMB produced by B cells promoted GZMB + B cell proliferation in ERK1/2-dependent manner, facilitating GZMB + B cell expansion. However, GZMB + B cells tended to undergo apoptosis after prolonged stimulation, which may be considered a negative feedback mechanism to limit their uncontrolled expansion. Finally, we found that expanded GZMB + B cells exhibited a regulatory phenotype and were enriched in CD307b hi , CD258 hi CD72 hi , and CD21loPD-1 hi B cell subpopulations. Our study, to our knowledge, provides new insight into biology of GZMB + B cells and an efficient method to expand GZMB + B cells for future cell therapy applications.

No abstract

No abstract